Notices. Notice
1,550 words·~7 min read·
/register/2022/10/24/2022-23028·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2013-N-0134] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mammography Quality Standards Act Requirements AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget
(OMB)for review and clearance under the Paperwork Reduction Act of 1995. DATES: Submit written comments (including recommendations) on the collection of information by November 23, 2022. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0309. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, *PRAStaff@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Mammography Quality Standards Act Requirements—21 CFR Part 900 OMB Control Number 0910-0309—Extension The Mammography Quality Standards Act (Pub. L. 102-539) requires the establishment of a Federal certification and inspection program for mammography facilities; standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. Implementing regulations are found in part 900 (21 CFR part 900). The regulations are intended to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body (AB). This requires undergoing a review of their clinical images and providing the AB with information showing that they meet the equipment, personnel, quality assurance, and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer complaint mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA-approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis. FDA meets with its National Mammography Quality Assurance Advisory Committee (NMQAAC) for the purposes of advising FDA's mammography program on advances in mammography technology and procedures and on appropriate quality standards for mammography facilities. NMQAAC is made up of representatives of the mammography community, consumer and industry groups, and government. The meetings are open to the public and time is allotted for public statements on issues of concern in the mammography field. The chairperson may also call upon attendees to contribute to the committee discussions. FDA also regularly meets or holds teleconferences with its approved accreditation bodies and State certification agencies to discuss issues of mutual concern. We also engage with the Conference of State Radiation Program Directors (CRCPD), a professional organization of State agencies concerned with radiation protection. The CRCPD has established a standing Mammography Committee, which meets with FDA mammography staff at least once a year. Finally, in recent years, FDA mammography staff have met several times with representatives of manufacturers working on the new applications of digital technology in mammography to resolve problems preventing the making of that technology generally available. FDA mammography staff have also worked with representatives of the manufacturers to develop quality assurance manuals for full field digital mammography units. In the **Federal Register** of August 8, 2022 (87 FR 48678), we published a notice soliciting public comment of the proposed information collection. No comments were received. We estimate the burden of this collection of information as follows: Table 1—Estimated Annual Reporting Burden Activity/21 CFR section/FDA form No. Number of respondents Number of responses per respondent Total annual responses Average burden per response Total hours 1 Notification of intent to become an AB—900.3(b)(1) 0.33 1 0.33 1 1 Application for approval as an AB; full 2 —900.3(b)(3) 0.33 1 0.33 320 106 Application for approval as an AB; limited 3 —900.3(b)(3) 5 1 5 30 150 AB renewal of approval—900.3(c) 1 1 1 15 15 AB application deficiencies—900.3(d)(2) 0.1 1 0.1 30 3 AB resubmission of denied applications—900.3(d)(5) 0.1 1 0.1 30 3 Letter of intent to relinquish accreditation authority—900.3(e) 0.1 1 0.1 1 1 Summary report describing all facility assessments—900.4(f) 330 1 330 7 2,310 AB reporting to FDA; facility 4 —900.4(h) 8,718 1 8,718 1 8,718 AB reporting to FDA; AB 5 —900.4(h) 5 1 5 10 50 AB financial records—900.4(i)(2) 1 1 1 16 16 Former AB new application—900.6(c)(1) 0.1 1 0.1 60 6 Reconsideration of accreditation following appeal—900.15(d)(3)(ii) 1 1 1 2 2 Application for alternative standard—900.18(c) 2 1 2 2 4 Alternative standard amendment—900.18(e) 10 1 10 1 10 Certification agency application—900.21(b) 0.33 1 0.33 320 106 Certification agency application deficiencies—900.21(c)(2) 0.1 1 0.1 30 3 Certification electronic data transmission—900.22(h) 5 200 1,000 0.083 (5 minutes) 83 Changes to standards—900.22(i) 2 1 2 30 60 Certification agency minor deficiencies—900.24(b) 1 1 1 30 30 Appeal of adverse action taken by FDA—900.25(a) 0.2 1 0.2 16 3 Inspection fee exemption—FDA Form 3422 419 1 419 0.25 (15 minutes) 105 Total 11,785 1 Numbers have been rounded. 2 One time burden. 3 Refers to accreditation bodies applying to accredit specific full-field digital mammography units. 4 Refers to the facility component of the burden for this requirement. 5 Refers to the AB component of the burden for this requirement. Table 2—Estimated Annual Recordkeeping Burden Activity/21 CFR section Number of recordkeepers Number of records per recordkeeper Total annual records Average burden per recordkeeping Total hours 1 AB transfer of facility records—900.3(f)(1) 0.1 1 0.1 0 1 Consumer complaints system; AB—900.4(g) 5 1 5 1 5 Documentation of interpreting physician initial requirements—900.12(a)(1)(i)(B)(2) 87 1 87 8 696 Documentation of interpreting physician personnel requirements—900.12(a)(4) 8,718 4 34,872 1 34,872 Permanent medical record—900.12(c)(4) 8,718 1 8,718 1 8,718 Procedures for cleaning equipment—900.12(e)(13) 8,718 52 453,336 0.083 (5 minutes) 37,627 Audit program—900.12(f) 8,718 1 8,718 16 139,488 Consumer complaints system; facility—900.12(h)(2) 8,718 2 17,436 1 17,436 Certification agency conflict of interest—900.22(a) 5 1 5 1 5 Processes for suspension and revocation of certificates—900.22(d) 5 1 5 1 5 Processes for appeals—900.22(e) 5 1 5 1 5 Processes for additional mammography review—900.22(f) 5 1 5 1 5 Processes for patient notifications—900.22(g) 3 1 3 1 3 Evaluation of certification agency—900.23 5 1 5 20 100 Appeals—900.25(b) 5 1 5 1 5 Total 238,971 1 Total hours have been rounded. Table 3—Estimated Annual Third-Party Disclosure Burden Activity/21 CFR section Number of respondents Number of disclosures per respondent Total annual disclosures Average burden per disclosure Total hours 1 Notification of facilities that AB relinquishes its accreditation—900.3(f)(2) 0.1 1 0.1 200 20 Clinical images; facility 2 —900.4(c), 900.11(b)(1), and 900.11(b)(2) 2,885 1 2,885 1.44 4,154 Clinical images; AB 3 —900.4(c) 5 1 5 416 2,080 Phantom images; facility 2 —900.4(d), 900.11(b)(1), and 900.11(b)(2) 2,885 1 2,885 0.72 (43 minutes) 2,077 Phantom images; AB 3 —900.4(d) 5 1 5 208 1,040 Annual equipment evaluation and survey; facility 2 —900.4(e), 900.11(b)(1), and 900.11(b)(2) 8,718 1 8,718 1 8,718 Annual equipment evaluation and survey; AB 3 —900.4(e) 5 1 5 1,730 8,650 Provisional mammography facility certificate extension application—900.11(b)(3) 0 1 0 0.5 (30 minutes) 1 Mammography facility certificate reinstatement application—900.11(c) 281 1 281 5 1,405 Lay summary of examination—900.12(c)(2) 8,718 5,085 44,331,030 0.083 (5 minutes) 3,679,475 Lay summary of examination; patient refusal 4 —900.12(c)(2) 87 1 87 0.5 (30 minutes) 44 Report of unresolved serious complaints—900.12(h)(4) 20 1 20 1 20 Information regarding compromised quality; facility 2 —900.12(j)(1) 20 1 20 200 4,000 Information regarding compromised quality; AB 3 —900.12(j)(1) 20 1 20 320 6,400 Patient notification of serious risk—900.12(j)(2) 5 1 5 100 500 Reconsideration of accreditation—900.15(c) 5 1 5 2 10 Notification of requirement to correct major deficiencies—900.24(a) 0.4 1 0.4 200 80 Notification of loss of approval; major deficiencies—900.24(a)(2) 0.15 1 0.15 100 15 Notification of probationary status—900.24(b)(1) 0.3 1 0.3 200 60 Notification of loss of approval; minor deficiencies—900.24(b)(3) 0.15 1 0.15 100 15 Total 3,718,764 1 Total hours have been rounded. 2 Refers to the facility component of the burden for this requirement. 3 Refers to the AB component of the burden for this requirement. 4 Refers to the situation where a patient specifically does not want to receive the lay summary of her exam. Respondents use the Mammography Program Reporting and Information System to submit information. Our estimated burden for the information collection reflects an overall increase of 28,664 hours and a corresponding increase of 9,137,449 responses/records. We attribute this adjustment to an increase in the number of submissions we received over the last few years. We do not include burden for §§ 900.12(c)(1) and (3), 900.3(f)(1), and 900.24(c) because if a certifying State had its approval withdrawn, FDA would take over certifying authority for the affected facilities. Because FDA already has all the certifying State's electronic records, we assume no additional reporting burden. Dated: October 18, 2022. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2022-23028 Filed 10-21-22; 8:45 am]
Connectionstraces to 1
Traces to 1 document
2 references not yet in our index
- 21 CFR 900
- Pub. L. 102-539
Citation graph
cites case law
Cites 3Cited by 0 across 0 sources